Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 36, 2013, Pages

  Chang, Yong S ^a   Graves, Bradford ^b   Guerlavais, Vincent ^a   Tovar, Christian ^b   Packman, Kathryn ^b   To, Kwong Him ^b   Olson, Karen A ^a   Kesavan, Kamala ^a   Gangurde, Pranoti ^a   Mukherjee, Aditi ^a   Baker, Theresa ^a   Darlak, Krzysztof ^a   Elkin, Carl ^a   Filipovic, Zoran ^b   Qureshi, Farooq Z ^b   Cai, Hongliang ^a   Berry, Pamela ^b   Feyfant, Eric ^a   Shi, Xiangguo E ^a   Horstick, James ^a   Annis, D Allen ^a   Manning, Anthony M ^a   Fotouhi, Nader ^b   Nash, Huw ^a   Vassilev, Lyubomir T ^b   Sawyer, Tomi K ^a   more..

^a Aileron Therapeutics Inc   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; ATSP 7041; HYDROCARBON; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UNCLASSIFIED DRUG; ATSP-7041; CYCLOPEPTIDE; PEPTIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL ACTIVITY; CELL FUNCTION; CELL MEMBRANE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; X RAY ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; FEMALE; HCT116 CELL LINE; LONG EVANS RAT; MALE; MCF 7 CELL LINE; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; RAT; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BINDING, COMPETITIVE; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; FEMALE; HCT116 CELLS; HUMANS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; RATS, LONG-EVANS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883432191     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303002110     Document Type: Article

References (46)

1. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8(1):25-37.
2. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307-310.
3. Bernal F, et al. (2010) A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18(5):411-422.
4. Marine JC (2011) MDM2 and MDMX in cancer and development. Curr Top Dev Biol 94:45-75.
5. Migliorini D, et al. (2002) Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22(15):5527-5538. (Pubitemid 34755762)
6. Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7(1):1-11.
7. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296-299. (Pubitemid 27220766)
8. Onel K, Cordon-Cardo C (2004) MDM2 and prognosis. Mol Cancer Res 2(1):1-8. (Pubitemid 38167102)
9. Gembarska A, et al. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18:1239-1247.
10. Macchiarulo AGN, Carotti A, Moretti F, Pellicciari R (2011) Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4). Med Chem Commun 2:455-465.
11. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844-848. (Pubitemid 38174664)
12. Tovar C, et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 103(6):1888-1893. (Pubitemid 43228788)
13. Fry DC, Graves B, Vassilev LT (2005) Development of E3-substrate (MDM2-p53)-binding inhibitors: Structural aspects. Methods Enzymol 399:622-633. (Pubitemid 41772757)
14. Graves B, et al. (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 109(29):11788-11793.
15. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 129(9):2456-2457. (Pubitemid 46364050)
16. Brown CJ, et al. (2013) Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8(3):506-512.
17. Schafmeister CJ, Po J, Verdine GL (2000) An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc 122:5891-5892. (Pubitemid 30432299)
18. Kim YW, Grossmann TN, Verdine GL (2011) Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat Protoc 6(6):761-771.
19. Blackwell HE, et al. (2001) Ring-closing metathesis of olefinic peptides: Design, synthesis, and structural characterization of macrocyclic helical peptides. J Org Chem 66(16):5291-5302. (Pubitemid 32878878)
20. Boal AK, et al. (2007) Facile and E-selective intramolecular ring-closing metathesis reactions in 3(10)-helical peptides: A 3D structural study. J Am Chem Soc 129(22):6986-6987. (Pubitemid 46903250)
21. Benedetti E, et al. (1982) Peptaibol antibiotics: A study on the helical structure of the 2-9 sequence of emerimicins III and IV. Proc Natl Acad Sci USA 79(24):7951-7954. (Pubitemid 13194108)
22. Crisma M, Formaggio F, Moretto A, Toniolo C (2006) Peptide helices based on alpha-amino acids. Biopolymers 84(1):3-12.
23. Williams RM, Im M-N (1991) Asymmetric synthesis of mono-substituted and alpha, alpha-disubstituted alpha-amino acids via diastereoselective glycine enolate alkylations. J Am Chem Soc 113:9276-9286.
24. Yang JT, Wu CS, Martinez HM (1986) Calculation of protein conformation from circular dichroism. Methods Enzymol 130:208-269.
25. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66(Pt 2):125-132.
26. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67(Pt 4):235-242.
27. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 (Pt 3):240-255. (Pubitemid 27235885)
28. Popowicz GM, et al. (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6(19):2386- 2392.
29. Brünger AT, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54(Pt 5):905-921.
30. Kenakin T (1993) Synoptic receptor function. Trends Pharmacol Sci 14(12):431-432.
31. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67(18):8810-8817. (Pubitemid 47437457)
32. Phan J, et al. (2010) Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 285(3):2174-2183.
33. Pazgier M, et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 106(12):4665-4670.
34. Böttger V, et al. (1999) Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18(1):189-199. (Pubitemid 29060593)
35. Kussie PH, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274(5289):948-953. (Pubitemid 26398409)
36. Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist's guide to molecular interactions. J Med Chem 53(14):5061-5084.
37. Baek S, et al. (2012) Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc 134(1):103-106.
38. Stewart ML, Fire E, Keating AE, Walensky LD (2010) The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6(8):595-601.
39. Phillips C, et al. (2011) Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc 133(25):9696-9699.
40. Ray-Coquard I, et al. (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study. Lancet Oncol 13(11):1133-1140.
41. Marine JC, Dyer MA, Jochemsen AG (2007) MDMX: From bench to bedside. J Cell Sci 120(Pt 3):371-378. (Pubitemid 46332500)
42. Ramos YF, et al. (2001) Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 61(5):1839-1842. (Pubitemid 32691995)
43. Danial NN, et al. (2008) Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14(2):144-153. (Pubitemid 351214557)
44. Walensky LD, et al. (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305(5689):1466-1470. (Pubitemid 39167667)
45. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D (2011) An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 7(9):585-587.
46. Moellering RE, et al. (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462(7270):182-188.